Human pharmaceutical business
Eli Lilly’s (LLY) human pharmaceutical business reported revenues of $5.0 billion in 2Q17, an 11.0% rise compared to $4.5 billion in 2Q16. Eli Lilly’s new products include Basaglar, Lartruvo, Cyramza, Olumiant, Jardiance, Taltz, and Trulicity.
The above chart shows revenues for new products over the last few quarters. Let’s look next at the performances of each of the products.
Basaglar, an insulin glargine injection to control blood sugar levels in people with diabetes, reported revenues of $86.6 million in 2Q17, including US sales of $60.0 million and international sales of $27.0 million. The drug was launched in US markets in 4Q16.
Lartruvo, a drug for the treatment of people with advanced soft tissue sarcoma, reported revenues of $47.4 million in 2Q17. The drug was launched in the United States as well as European markets in 4Q16.
Cyramza, an oncology drug for the treatment of metastatic non-small cell lung cancer, metastatic colorectal cancer, and advanced gastric cancer, reported a rise of 27.0% in 2Q17 sales to $186.3 million compared to 2Q16. The rise was driven by strong sales in European and Japanese markets.
Jardiance, a drug used to lower blood sugar levels in people with type 2 diabetes, is part of the diabetes alliance between Eli Lilly and Boehringer Ingelheim. Jardiance reported sales of $103.2 million in 2Q17, driven by increased demand across the US and international markets.
Taltz, a drug for the treatment of plaque psoriasis, reported revenues of $138.7 million in 2Q17. The drug was launched in the US and European markets in 2Q16. US markets contribute a major portion of Taltz sales, reporting sales of $124.0 million in 2Q17.
Trulicity, a drug for improving blood sugar levels in people with type 2 diabetes, reported more than 100% growth in its 2Q17 sales to $480.2 million compared to $201.3 million in 2Q16. Growth was driven by increased demand in US markets.